11/8
02:32 pm
okur
OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
11/5
04:05 pm
okur
OnKure to Present at the Stifel 2024 Healthcare Conference
Medium
Report
OnKure to Present at the Stifel 2024 Healthcare Conference
11/1
05:33 pm
okur
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
11/1
05:30 pm
okur
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
Low
Report
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
10/24
03:35 pm
okur
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]
Low
Report
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]
10/23
05:15 pm
okur
OnKure files to sell 2.94M shares of Class A Common Stock for holders [Seeking Alpha]
Medium
Report
OnKure files to sell 2.94M shares of Class A Common Stock for holders [Seeking Alpha]
10/17
10:38 am
okur
OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/11
06:05 am
okur
OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
10/10
02:55 pm
okur
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm [Yahoo! Finance]
Neutral
Report
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm [Yahoo! Finance]
10/10
08:33 am
okur
OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $35.00 price target on the stock.
Low
Report
OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $35.00 price target on the stock.
10/8
06:27 am
okur
Upcoming Stock Splits This Week (October 7 to October 11) – Stay Invested [Yahoo! Finance]
Medium
Report
Upcoming Stock Splits This Week (October 7 to October 11) – Stay Invested [Yahoo! Finance]
10/7
04:52 am
okur
OnKure and Reneo Pharmaceuticals complete merger [Yahoo! Finance]
Medium
Report
OnKure and Reneo Pharmaceuticals complete merger [Yahoo! Finance]